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Improved Blood Flow?
Peripheral vascular disease (PVD) refers to the clinical manifestations of 
reduced blood flow to the legs, usually secondary to atherosclerosis.  
Depending on the extent and severity of the blood flow reduction, patients 
with PVD are often severely limited by pain in their legs with ambulation 
(termed claudication) which can progress to limb threatening ischemia 
requiring surgical revascularization or amputation.  In some patients with 
PVD, blood flow to the legs is maintained by the development of collateral 
blood vessels that “bypass” the flow limiting atherosclerotic lesions.  
Because none of the currently available therapeutic agents enhance blood 
flow in patients with PVD, there is an enormous effort in industry and 
academic laboratories to develop approaches to augment the growth and 
development of collateral blood vessels.  We have shown that HPTPβ, a 
protein tyrosine phosphatase (PTP) expressed primarily in vascular 
endothelial cells, is a negative regulator of the VEGFR2 and Tie2 signaling 
pathways, two pathways known to promote new blood vessel growth 
(angiogenesis) and to augment collateral blood flow in animal models of 
PVD.  Based on these studies we hypothesized that inhibition of HPTPβ
would improve blood flow to ischemic tissues by enhancing the activation 
of VEGFR2 and Tie2.  To test this hypothesis, potent and selective HPTPβ
inhibitors have been developed. Several of these inhibitors had nanomolar
IC50 and were at least 100 fold selective for HPTPβ over other 
phosphatase enzymes.  In addition, a number of the inhibitors also 
enhanced the activation and biological activity of Tie2 and VEGFR2 in 
endothelial cells and augmented Tie2 activation in vivo.  Consistent with 
our hypothesis, these inhibitors also enhanced new blood vessel 
development in an ex vivo model of angiogenesis, the rat aortic ring model 
and in vivo in a rat model of PVD.  If successful, HPTPβ inhibitors could 
provide breakthrough therapy for patients with PVD and other ischemic 
cardiovascular diseases such as coronary vascular disease and cerebral 
vascular disease.
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Fully human antibodies are derived from 
human cDNA libraries or from mice 
engineered to express the human IgG gene and 
therefore contain no murine sequences.  
